Skip to main
RLAY
RLAY logo

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics Inc is positioned for a favorable outlook due to its novel RLY-2608 candidate, which is anticipated to enhance the market penetration of PI3Ka inhibitors with a best-in-class profile. The clinical data for RLY-2608 suggests improvements in both efficacy and tolerability compared to existing treatments like capivasertib, potentially leading to swift market adoption. Additionally, the success of capivasertib, which has surpassed alpelisib sales and expanded the market to approximately $700 million, indicates a growing opportunity for Relay's innovative therapies in the oncology sector.

Bears say

The financial outlook for Relay Therapeutics Inc. appears negative due to a substantial expected decline in median progression-free survival (mPFS) from 24 months to just 5 months, raising concerns about the efficacy of their treatment candidates. Additionally, safety liabilities related to inavolisib's mechanism of action have hindered its commercial launch, resulting in performance that falls short of initial projections for a first-line product. The company's challenges are compounded by declining sales in competitive markets, as evidenced by the 8% drop in sales of similar oncology products, indicating potential struggles within the market landscape.

RLAY has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Strong Buy based on their latest research and market trends.

According to 6 analysts, RLAY has a Strong Buy consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.